Detecting Alzheimer's disease biomarkers through blood tests at the point of care
Official title: Blood-based Alzheimer's biomarker detection at the point of care
Funded at Brigham and Women's Hospital · NIH-11170836 · Data updated 2026-11-12
This study is working on a simple blood test that could help doctors spot signs of Alzheimer's disease early, even before symptoms show up, making it easier for patients to get the care they need sooner.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $885,006 |
| NIH project number | 1R56AG087357-01 |
| Project ID | NIH-11170836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who may be at risk for Alzheimer's disease or are experiencing early signs of cognitive decline.
✕Less likely to help
Patients who are under 21 years old or those who do not exhibit any risk factors or symptoms of Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing a blood-based test to detect biomarkers associated with Alzheimer's disease (AD) at the point of care. By utilizing advancements in blood biomarkers like amyloid-beta and phosphorylated tau, the study aims to create a more accessible and less invasive method for early diagnosis of AD. This approach could allow for timely intervention and better management of the disease, potentially improving patient outcomes. The research will explore the effectiveness of these biomarkers in identifying AD before symptoms appear, making it a significant advancement in Alzheimer's care.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of Alzheimer's disease, allowing for timely treatment and management.
How similar studies have gone: Other research has shown promise in using blood-based biomarkers for Alzheimer's detection, indicating that this approach could be a viable alternative to traditional diagnostic methods.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Shafiee, Hadi — Brigham and Women's Hospital
- Study coordinator: Shafiee, Hadi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.